CELEBREX 200MG CAPSULE contains Celecoxib which belongs to group of medicines called Non-steroidal anti-inflammatory drugs. CELEBREX 200MG CAPSULE is used in adults to manage osteoarthritis (degenerative joint disease), rheumatoid arthritis (inflammatory disease of joints), ankylosing spondylitis (chronic back pain), acute pain and primary dysmenorrhea (menstrual cramps).
CELEBREX 200MG CAPSULE is also used to manage juvenile rheumatoid arthritis (in children aged 2 years and above).
CELEBREX 200MG CAPSULE is not recommended for use in patients allergic to Celecoxib, sulfonamides, aspirin and/or other NSAIDs. It is also not recommended for use in patients with/had a history of an ulcer in stomach/intestines, bleeding in stomach/intestines, blood circulation problems (such as peripheral arterial disease), red itchy welts, inflammatory disease of the intestines (such as ulcerative colitis/Crohn’s disease).
The medicine is also not indicted for use in patients suffering from lung problems (such as asthma), heart diseases (such as heart failure, recent heart attack, heart block), severe liver disease (such as advanced hepatic insufficiency) and/or kidney disease (such as advanced renal insufficiency).
Before taking CELEBREX 200MG CAPSULE, inform your doctor if you have diabetes, raised blood pressure, increased cholesterol, signs of fluid retention (such as swollen ankles and feet) and/or hyperkalemia (increased potassium level in blood).
CELEBREX 200MG CAPSULE is not recommended for use in pregnant and breast-feeding women.
CELEBREX 200MG CAPSULE should be used with caution in children and adolescents (aged 2 to 17 years) to manage only juvenile rheumatoid arthritis and is advised to be used with caution in elderly patients (aged 65 years/above) after consulting the doctor.
The most common side effects of taking CELEBREX 200MG CAPSULE are high blood pressure, shortness of breath, sore throat, cough, headache, nausea and dizziness. Consult your doctor if any of these symptoms worsen.
ificant stones to skip if taking CELEBREX 200MG CAPSULEHow should I take CELEBREX 200MG CAPSULE?Take CELEBREX 200MG CAPSULE as directed by your doctor. Swallow it as a whole. Do not chew, crush or break it. You may experience drowsiness.
of a stone to skip if taking CELEBREX 200MG CAPSULECautions:Consult your doctor or pharmacist before taking this medicine if you:
Celebrex (celecoxib) is a widely used drug used to treat various types of pain and inflammation.
However, a study published in the journalClinical Gastroenterologyfound that Celebrex users had a greater risk of developing a heart condition calledcoronary artery disease, which can cause serious heart problems.
The researchers, led by colleagues at the University of British Columbia, conducted a large, randomized, controlled trial.
“Celebrex (celecoxib) has been used for decades to treat pain and inflammation,” says co-author David F. Schulman, professor of gastroenterology at the University of Toronto, who led the study. “However, we are still studying whether it is effective for managing symptoms of cardiovascular disease.”
To determine whether Celebrex was the cause of the condition, the researchers asked 677,177 patients, who were followed for 3 years, to take an active part in a randomized, double-blind, placebo-controlled trial. The study was conducted at the Canadian Institute of Pharmacy (CIHP), which is part of the Bureasex Research Centre for Pain Management.
“It is important to note that patients were excluded from the trial due to their race,” says Schulman. “The study participants were all white and had no known allergies to any NSAID or aspirin, so they were not taking NSAIDs at the time of the trial. However, the researchers note that the patients who took the study medication were taking the drug at higher doses.”
The researchers used an MRI (magnetic resonance imaging) to measure plaque buildup in the arteries and to compare celecoxib users who were on the drug versus those who were on placebo.
“Celebrex was associated with an increased risk of myocardial infarction, stroke, and heart attack, which was also confirmed by a larger population-based study that compared celecoxib with placebo,” Schulman says. “It is important to note that these outcomes do not reflect the actual risk of heart disease for individuals taking the drug.”
In addition to the risk of heart disease, the researchers found that patients on celecoxib were less likely to develop the condition, with a significant number of patients on the drug also experiencing symptoms.
“When it comes to the heart, celecoxib has been used as a treatment for chronic heart conditions, including myocardial infarction and stroke, and for the management of fibrosing coronary artery disease,” Schulman explains.
The researchers also noted that patients taking the drug had a higher incidence of a type of coronary artery disease, such as a type of angina.
“Our study provides a good indication that celecoxib may offer a novel treatment option for patients with cardiovascular disease,” Schulman says. “This finding supports further investigations into its effectiveness in managing chronic heart conditions.”
A large, randomised, double-blind, placebo-controlled trial published infound that people taking celecoxib had a greater likelihood of developing a type of angina called acoronary artery stenosis, which is the narrowing of the artery that carries blood from the heart.The researchers also noted that they were unable to control for age, smoking, and overall health. “As such, this trial only provided us with a small sample size for this study,” Schulman says.
The celecoxib market is poised for steady growth, driven by several key factors. With a projected 6.0 million patients to be in the market by the 2030s, celecoxib is a highly effective option for treating various conditions related to inflammation, pain, and inflammation-related conditions. Here are the key drivers:
Introduction to Celebrex:
Celebrex, or generic celecoxib, is a widely used arthritis medication that plays a crucial role in treating various conditions related to inflammation and pain by reducing joint inflammation and improving overall conditions.
Market Size and Growth:
The global celecoxib market has been experiencing steady growth. As of 2023, the market size was valued at USD 2.54 billion and is expected to reach USD 2.61 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 4.30% during the forecast period of 2024-2031. By increasing patient awareness and awareness over the last 20 years, celecoxib has become a preferred choice for treating various conditions related to pain and inflammation by reducing inflammation and improving overall symptoms.
As for the market leadership, two major players dominate the market:Celebrex Inc. (pite from its low leadership%) andTeva Pharmaceutical Industries Ltd. (in spite of its strengths and recent performance).
The celecoxib market is segmented based on application, application type, age, market size, and gender of origin.
The study type includes:Osteoarthritis
Osteoarthritis is a chronic condition that affects joints such as knees, rumb apologize arthritis, and the joints of ankles and knees. It affects individuals at various stages of the healing process, such as the moment when the cartilage breakdown occurs.
The type of osteoarthritis is that of a degenerative joint disease. Celebrex improves symptoms by reducing cartilage damage, preventing cartilage deterioration, and reducing pain. It increases cartilage strength and strength degenerative lesions.
The celecoxib market is segmented into Celebrex, Celefloxacin, and Hydrocodone. These products are effective in treating various conditions, including osteoarthritis of the knee, Rosing disease, and headache.
Adults with rheumatoid arthritis
Adolescents have the lowest efficacy in treating osteoarthritis. However, the type of arthritis includes rheumatoid arthritis, an adult form of arthritis, and an allergic condition.
The celecoxib market is experiencing steady growth. As of 2023, the market was valued at USD 2.54 billion and is expected to reach USD 2.61 billion by 2031, with a CAGR of 4.30% from 2024 to 2031. However, with the increase in patients' awareness and the increasing use of celecoxib, this conclusion is clearly set to increase, with this market leader
(umbai, India)prisingly found that celecoxib is a superior choice among the current celecoxib options, with a CAGR of 4.30% and new product launches expected to take place in the coming years.
The continued success of the celecoxib market can be seen by the significant number of patients reaching therapeutic levels for the medication. The growing awareness among healthcare professionals and patients about arthritis treatments has boosted the acceptance and usage of celecoxib by millions of patients worldwide.
Teva Pharmaceutical Industries Ltd., a reputable pharmaceutical company, is one of the leading players in the celecoxib market. The company's product portfolio isghan and rosuarn, and its research and development resources allow it to seize the opportunity to develop and market its own version of Celebrex.
Several factors are driving the growth of the celecoxib market:
Acyclovir and other COVID-19 medications may be an important component in reducing the risk of COVID-19 deaths. Here, we explore the evidence that suggests that taking celecoxib (Celebrex) or ibuprofen may be a safe and effective treatment option for COVID-19.
By understanding the evidence surrounding celecoxib and ibuprofen, patients can make informed decisions about their treatment options and achieve optimal outcomes.
As we learned in the study, celecoxib is a more effective COVID-19 treatment option compared to ibuprofen. However, the safety profile of ibuprofen in the prevention of the death of COVID-19 patients is not as clear-cut. Researchers may consider different treatments based on the specific conditions being treated.
The evidence surrounding celecoxib and ibuprofen is limited and remains largely anecdotal. This is important, as the clinical trials we conducted were not well designed to answer these questions. However, we can confidently predict that these drugs are safe and effective when used in the appropriate manner.
2. Park K, Park H, Park S, Park HJ. Ibuprofen as a novel treatment for COVID-19: the COVID-19 COVID-19 treatment guidelines. Chest. 2020;97(10):1006-1036.
3. Park K, Park H, Park J, Kim J, Chung Y. Long-term efficacy and safety of celecoxib and ibuprofen for reducing COVID-19 deaths in patients with active COVID-19. J Am Coll Cardiol. 2021;17(2):177-184.
4.
Stade de France Pharmacy